Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Discovery Labs Stories

2013-05-07 08:31:09

WARRINGTON, Pa., May 7, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the first quarter ended March 31, 2013 and also provides certain program updates. Selected operational updates: SURFAXIN(®): On April 15, 2013, the Company reported that it had received from the U.S. Food and Drug Administration (FDA) a response to a previous...

2013-05-01 08:31:06

WARRINGTON, Pa., May 1, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to AFECTAIR(®), the Company's proprietary aerosol-conducting airway connector designed with the goal of simplifying and improving aerosolized medication delivery to infants requiring mechanical ventilation in the...

2013-04-15 08:28:33

WARRINGTON, Pa., April 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the U.S. Food and Drug Administration (FDA) has requested clarification and provided recommendations regarding the recently-updated product specifications for SURFAXIN(®). Discovery Labs plans to provide a response to the FDA within two months. FDA procedure provides up to...

2013-03-29 08:21:50

WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN(®) (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the Journal of Pediatric...

2013-03-06 16:26:41

WARRINGTON, Pa., March 6, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) will report fourth quarter 2012 results on Wednesday, March 13, 2013 before the open of the U.S. financial markets. The Company will also host a conference call at 10:00 a.m. ET that same day to discuss the fourth quarter financial results and other business updates. A question-and-answer session will follow management's remarks. To access the conference call and participate in the...

2013-02-13 16:26:41

WARRINGTON, Pa., Feb. 13, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a secured loan facility with Deerfield Management Company, L.P. (Deerfield) for up to $30.0 million in financing. Deerfield is a leading healthcare investment firm with more than $3.5 billion of assets currently under management. "We are encouraged...

2013-01-04 08:23:07

WARRINGTON, Pa., Jan. 4, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced changes to its board of directors and appointed a new Chief Executive Officer (CEO). The following changes are effective immediately: W. Thomas Amick, age 70, has resigned as Chairman of the board of directors and CEO. Mr. Amick served on the board since March 2004, was Chairman of...

2013-01-03 08:25:39

WARRINGTON, Pa., Jan. 3, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it has initiated the launch of its AFECTAIR(®) airway connector for infants receiving aerosolized medication in neonatal or pediatric intensive care units (NICU and PICU, respectively). The AFECTAIR device simplifies the delivery of aerosolized medication to critical care patients...

2012-12-04 08:28:23

WARRINGTON, Pa., Dec. 4, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the release of data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with SURFAXIN(® )may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia (BPD) when compared with reintubation rates of infants...

2012-11-28 08:29:41

WARRINGTON, Pa., Nov. 28, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced it will present both SURFAXIN(®) and AFECTAIR(®) data at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Hot Topics in Neonatology is an internationally recognized medical meeting dedicated to advancing the practice of neonatology. Earlier this year, SURFAXIN became the first Food and Drug Administration (FDA)-approved synthetic,...